The National Comprehensive Cancer Network has updated their guidelines for the treatment of ovarian cancer, including therapy for stage II-IV disease and persistent disease. READ MORE
Although Lynch syndrome is thought to increase the risk of colorectal and/or uterine cancer, certain mutations may confer an increased risk of breast or ovarian cancer.
The length of time between the end of adjuvant platinum-based therapy and the recurrence of cancer is a strong predictor of survival in older women with recurrent ovarian cancer.
A recent survey asked patients with primary and recurrent ovarian cancer to consider their reasons for choosing maintenance therapy following surgery and chemotherapy.